Product Introduction

The fluorecare® Cyfra21-1 Test Kit (Cytokeratin 19 Fragment) developed by Microprofit is a quantitative immunofluorescence assay (FIA) designed for the accurate detection of Cyfra21-1 levels in human serum and plasma. As part of the fluorecare® POCT diagnostic platform, this test kit enables rapid and reliable quantitative analysis, supporting efficient clinical decision-making in laboratories, hospitals, and point-of-care testing environments.

Detection Principle

The fluorecare® Cyfra21-1 test kit utilizes fluorescence immunochromatographic assay technology based on a double-antibody sandwich method. Cyfra21-1 in the sample binds with fluorescent-labeled antibodies to form antigen-antibody complexes, which are captured on the test line. The fluorescence signal is positively correlated with the Cyfra21-1 concentration and is detected and analyzed by the fluorecare® immunofluorescence analyzer, enabling accurate and quantitative measurement.

Clinical Applications

• Monitoring of non-small cell lung cancer (NSCLC)

• Auxiliary assessment of squamous cell carcinoma

• Evaluation of treatment response and tumor recurrence

• Support for prognosis in lung and bladder cancers

• Clinical laboratory and decentralized POCT testing

Frequently Asked Questions

Q: What is the fluorecare® Cyfra21-1 test kit used for?

A: The fluorecare® Cyfra21-1 test kit is used for quantitative detection of cytokeratin 19 fragment as a tumor marker, mainly for monitoring non-small cell lung cancer and squamous cell carcinoma.

Q: How fast is the fluorecare® Cyfra21-1 test?

A: The test provides accurate results within 15 minutes using the fluorecare® immunofluorescence analyzer.

Q: What samples can be used for this test?

A: Serum and plasma samples are suitable for testing with the fluorecare® Cyfra21-1 test kit.

Q: Is the fluorecare® Cyfra21-1 test suitable for POCT use?

A: Yes, it is specifically designed for point-of-care testing environments.

Compatible Analyzer

The fluorecare® Cyfra21-1 test kit is specifically designed to work with the fluorecare® immunofluorescence analyzer, providing fast, accurate, and quantitative results. This integrated POCT solution ensures efficient workflow and reliable performance for laboratories, clinics, and decentralized healthcare settings.

• Quantitative detection based on immunofluorescence assay (FIA)

• Rapid results within 15 minutes

• High sensitivity and specificity

• Seamless integration with fluorecare® POCT platform

• Stable performance with internal calibration

• User-friendly operation with minimal training required

• Suitable for laboratory and point-of-care testing scenarios